Boehringer Ingelheim is investing more than EUR 100 million ($125 million) at its Dortmund site to expand production capacity for the Respimat inhaler to 44 million units per year. Boehringer Ingelheim microParts GmbH manufactures the iRespimat inhaler in Dortmund for the global market.

In September 2004, Boehringer Ingelheim acquired the microtechnology company STEAG microParts GmbH and integrated it into the group. There are now more than 550 employees working at Boehringer Ingelheim microParts GmbH in Dortmund, where the Respimat inhaler is produced.

At the company headquarters in Ingelheim, Germany, the inhalers are filled with the relevant active pharmaceutical ingredients and then distributed worldwide. Here, Boehringer Ingelheim is investing additional EUR 72 million ($90 million) in the expansion of the Respimat production.

Source: Boehringer Ingelheim